arrow
G

Giulio Metro

University of Perugia
H指数:42
被引数:5,782

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2

NeoCOAST-2研究中可切除肺癌的循环肿瘤DNA清除与预后

Nature
IF48.5
2026-10-250
PRE
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)

EGFR突变型非小细胞肺癌对一线奥希替尼进展:真实世界中的再活检及二线疗法的影响(“Rebiopsy on Osi”研究)

2026-07-250
OAAI
A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

SAVANNAH研究的大众语言摘要:色瑞替尼联合奥希替尼用于EGFR突变型晚期非小细胞肺癌患者,这些患者的肿瘤在奥希替尼治疗后出现MET过表达和/或扩增,且肿瘤已进展或扩散。

2026-07-160
OA
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

EGFR突变晚期非小细胞肺癌患者在接受一线奥希替尼治疗后,接受卡铂联合培美曲塞二线治疗的实际疗效:一项国际多中心队列研究

2025-10-160
PRE
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

基因组匹配疗法在晚期实体瘤中的应用:随机II期ROME试验

2025-09-290
OAAI
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较(FRONT-BRAF):一项多中心、回顾性队列研究

2025-09-290
PRE
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

III期不可切除非小细胞肺癌接受度鲁瓦姆布巩固治疗后后续治疗策略的真实世界结局

2025-06-010
OAAI
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)

一项关于免疫治疗时代下,临床医生对晚期非小细胞肺癌(NSCLC)及体力状态较差患者的态度与生存结局的前瞻性研究:PICASO(GOIRC-04-2020)。

2025-06-010
PRE
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
2025-05-310
OAAI
Non-adenocarcinoma histology in patients with RET plus lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry

RET融合阳性肺癌患者中的非腺癌组织学特征:来自RET-MAP登记研究的RET抑制剂疗效与生存分析

2024-09-010
PRE
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer
2024-09-010
PRE
A prospective study on clinicians' attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020)

一项关于免疫治疗时代下,临床医生对体力状态较差的非小细胞肺癌(NSCLC)患者的态度及生存结局的前瞻性研究:PICASO研究(GOIRC-04-2020)。

2024-09-010
PRE
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab
2024-08-064
OAAI
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI